17817-31-1
基本信息
4',6,7-三羟基异黄酮
6,7,4'-TRIHYDROXYISOFLAVONE
DEMETHYLTEXASIN
TRIHYDROXYISOFLAVONE, 4',6,7-
TRIHYDROXYISOFLAVONE, 4',6,7-(RG)
6,7-Dihydroxy-3-(4-hydroxyphenyl)-4H-chromen-4-one
物理化学性质
熔点 | >280℃ |
沸点 | 587.1±50.0 °C(Predicted) |
密度 | 1.548±0.06 g/cm3(Predicted) |
储存条件 | 2-8°C |
溶解度 | 溶于二甲基甲酰胺 |
酸度系数(pKa) | 6.85±0.20(Predicted) |
形态 | 粉末晶体 |
颜色 | 淡黄色至棕色至深绿色 |
LogP | 2.170 (est) |
CAS 数据库 | 17817-31-1(CAS DataBase Reference) |
安全数据
危险性符号(GHS) | GHS05,GHS06,GHS08,GHS09 |
警示词 | 危险 |
危险性描述 | H330-H302-H314-H370-H372-H373-H341-H350-H411-H290 |
防范说明 | P501-P273-P260-P270-P202-P234-P201-P271-P264-P280-P284-P390-P391-P308+P311-P303+P361+P353-P301+P330+P331-P363-P301+P312+P330-P304+P340+P310-P305+P351+P338+P310-P403+P233-P406-P405 |
安全说明 | S22-S24/25 |
WGK Germany | 3 |
F | 10 |
海关编码 | 2914.69.9000 |
常见问题列表
CDK1
|
CDK2
|
PKC
|
Desmethylglycitein (4',6,7-Trihydroxyisoflavone)(0-100 μM; 24-72 hours) suppesses anchorage-dependent growth of HCT-116 and DLD1 cells in a dose- and time-dependent manner without cytotoxicity . Desmethylglycitein (4',6,7-Trihydroxyisoflavone)(0-100 μM; 24-72 hours) suppresses CDK1 activity in a dose-dependent manner and inhibits CDK2 activity in HCT-116 cells. Desmethylglycitein (4',6,7-Trihydroxyisoflavone)(0-100 μM; 24-72 hours) induces cell cycle arrest at the S and G2/M phases, the percentage of cells in S phase is higher in the 100 μM 6,7,4′-THIF-treated group, and the same pattern is observed in G2/M phase (29.5% versus 19.1% ) .
Cell Viability Assay
Cell Line: | HCT-116 cells |
Concentration: | 0, 12.5, 25, 50 or 100 μM |
Incubation Time: | 24, 48 or 72 hours |
Result: | Inhibited anchorage-dependent and -independent growth of HCT-116 cells. |
Western Blot Analysis
Cell Line: | HCT-116 and DLD1 cells |
Concentration: | 0, 25, 50 or 100 μM |
Incubation Time: | 48 hours |
Result: | Inhibited CDK1,CDK2 expression. |
Cell Cycle Analysis
Cell Line: | HCT-116 cells |
Concentration: | 0, 25, 50 or 100 μM |
Incubation Time: | 24, 48 or 72 hours |
Result: | Induces cell cycle arrest of HCT-116 cells at S and G2/M phases. |
Desmethylglycitein (4',6,7-Trihydroxyisoflavone) (intraperitoneally injection; 5 or 25 mg/kg; once daily; 20 days) suppresses tumor development in mice and serves as an effective anticancer treatment with the potential to inhibit or delay the tumorigenicity of HCT-116 cells in an in vivo system.
Animal Model: | Female athymic nude mice subcutaneously injected with HCT-116 cells |
Dosage: | 5 or 25 mg/kg |
Administration: | Intraperitoneally injection; 5 or 25 mg/kg; once daily; 20 days |
Result: | Decreased tumor growth, volume and weight of HCT-116 xenografts. |